Osmotica Pharmaceuticals (NASDAQ:OSMT) Lowered to Equal Weight at Wells Fargo & Co

Wells Fargo & Co cut shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from an overweight rating to an equal weight rating in a report released on Monday morning, The Fly reports. Wells Fargo & Co currently has $4.00 target price on the stock.

OSMT has been the subject of a number of other research reports. SVB Leerink began coverage on shares of Osmotica Pharmaceuticals in a research report on Friday, March 6th. They set an outperform rating and a $10.00 target price for the company. SunTrust Banks began coverage on shares of Osmotica Pharmaceuticals in a research report on Wednesday, March 18th. They set a buy rating and a $8.00 target price for the company. BidaskClub cut shares of Osmotica Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, February 4th. Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, January 21st. Finally, ValuEngine raised shares of Osmotica Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, February 4th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Osmotica Pharmaceuticals presently has a consensus rating of Buy and an average price target of $8.36.

NASDAQ OSMT opened at $3.80 on Monday. The company has a debt-to-equity ratio of 2.36, a quick ratio of 1.99 and a current ratio of 2.27. The firm’s 50 day moving average price is $5.08 and its 200-day moving average price is $5.25. Osmotica Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $7.97. The company has a market cap of $212.78 million and a PE ratio of -0.74.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.52). Osmotica Pharmaceuticals had a negative net margin of 112.57% and a negative return on equity of 5.97%. The business had revenue of $59.91 million for the quarter, compared to the consensus estimate of $53.88 million. On average, analysts forecast that Osmotica Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.

In related news, Director Sriram Venkataraman purchased 1,250,000 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was acquired at an average price of $5.00 per share, with a total value of $6,250,000.00. Following the completion of the acquisition, the director now owns 22,485,297 shares in the company, valued at approximately $112,426,485. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Osmotica Pharmaceuticals by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 137,926 shares of the company’s stock worth $964,000 after buying an additional 32,740 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Osmotica Pharmaceuticals by 168.6% in the fourth quarter. Bank of America Corp DE now owns 12,289 shares of the company’s stock worth $86,000 after buying an additional 7,713 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Osmotica Pharmaceuticals by 233.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 81,565 shares of the company’s stock worth $570,000 after buying an additional 57,115 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Osmotica Pharmaceuticals in the fourth quarter worth $354,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Osmotica Pharmaceuticals in the fourth quarter worth $152,000. 6.81% of the stock is owned by institutional investors and hedge funds.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Further Reading: Inverted Yield Curve

The Fly

Analyst Recommendations for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.